Clinical trials: Primary Sclerosing Cholangitis, active
Primary Sclerosing Cholangitis
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC) during the double-blind period, an initial 96 week open-label extension (OLE) period, and an optional…
- Trial name
- ELMWOOD (NCT05627362)
- Testing
- Elafibranor 80 mg, Elafibranor 120 mg
- Where
- 62 sites in United States, Canada and 5 more
- Volunteers
- 68 people
- Sponsor
- Ipsen
Primary Sclerosing Cholangitis
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC).
- Trial name
- ELASCOPE (NCT07387549)
- Testing
- Elafibranor
- Where
- 231 sites in United States, Argentina and 23 more
- Volunteers
- 350 people
- Sponsor
- Ipsen
Primary Sclerosing Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible…
- Trial name
- VISTAS (NCT04663308)
- Testing
- Volixibat
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 182 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease.
- Trial name
- NCT04685200
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition.
- Trial name
- DRIVE-UP (NCT07341282)
- Testing
- Vancomycin (blinded), Vancomycin (open-label extension)
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- McMaster University
Chronic Hepatic Pruritus, Cholestatic Liver Disease
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.
- Conditions
- Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis
- Trial name
- NCT07843420
- Testing
- Nemolizumab-ilto
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
FARGO is a randomised, phase IIa, multi-centre, placebo-controlled trial to compare Faecal Microbiota Transplant (FMT) with placebo in patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease.
- Trial name
- FARGO (NCT06286709)
- Testing
- Faecal Microbiota Transplant
- Where
- 5 sites in United Kingdom
- Volunteers
- 58 people
- Sponsor
- University of Birmingham
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis.
- Conditions
- Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), Pediatric Inflammatory Bowel Diseases
- Trial name
- VERDA (NCT07646223)
- Testing
- Oral Vancomycin
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Tampere University Hospital
Autoimmune Liver Disease, Primary Sclerosing Cholangitis
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Trial name
- NCT03175471
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Autoimmune Liver Disease, Autoimmune Hepatitis
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- NCT03178630
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD).
- Trial name
- ALINK (NCT05750498)
- Testing
- No interventions
- Where
- 8 sites in United States
- Volunteers
- 800 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Training and Validation Data Collection Study
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD TVDCS (NCT06675604)
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 4,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Sclerosing Cholangitis
Detoxification of the Liver In PSC (Dolphin)
This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis.
- Trial name
- DOLPHIN (NCT05835505)
- Testing
- BRS201
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Brigham and Women's Hospital
Primary Sclerosing Cholangitis, Liver Transplant, Complications
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort…
- Conditions
- Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
- Trial name
- NCT06905054
- Testing
- Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis, Liver Diseases
Primary Sclerosing Cholangitis in Children
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine.
- Conditions
- Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
- Trial name
- NCT04181138
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Arbor Research Collaborative for Health
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Primary Sclerosing Cholangitis (PSC)
Biodegradable Stents in Primary Sclerosing Cholangitis
In patients with PSC, endoscopic therapy of strictures aims to improve cholestasis by relieving the biliary obstruction via endoscopic biliary dilatation with consideration of plastic stents in strictures refractory to dilatation…
- Trial name
- BSTPSC (NCT07607353)
- Testing
- archimedes stent
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College Hospital NHS Trust
Primary Sclerosing Cholangitis
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC).
- Trial name
- NCT06197308
- Testing
- oral vancomycin and oral amoxicillin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Minnesota
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital